Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways

References

• Christophers E. Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320.
   PubMed Web of Science ®Google Scholar
• Martin G, Guerard S, Fortin MM, et al. Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Lab Invest. 2012;92:1058–1070.
   PubMed Web of Science ®Google Scholar
• Works MG, Yin F, Yin CC, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014;193:3278–3287.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Iwasaki K, Tang W, et al. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18:5.
   PubMed Web of Science ®Google Scholar
• Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auckl). 2016;6:153–163.
   PubMedGoogle Scholar
• Castellsague J, Kuiper JG, Pottegard A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310.
   PubMed Web of Science ®Google Scholar
• Bao Q, Shen X, Qian L, et al. Anti-diabetic activities of catalpol in db/db mice. Korean J Physiol Pharmacol. 2016;20:153–160.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang Y, Liu Z, et al. Antidiabetic and antioxidant effects of catalpol extracted from Rehmannia glutinosa (Di Huang) on rat diabetes induced by streptozotocin and high-fat, high-sugar feed. Chin Med. 2016;11:25.
   PubMed Web of Science ®Google Scholar
• Jin D, Cao M, Mu X, et al. Catalpol Inhibited the Proliferation of T24 Human Bladder Cancer Cells by Inducing Apoptosis Through the Blockade of Akt-Mediated Anti-apoptotic Signaling. Cell Biochem Biophys. 2015;71:1349–1356.
   PubMed Web of Science ®Google Scholar
• Wang ZH, Zhan-Sheng H. Catalpol inhibits migration and induces apoptosis in gastric cancer cells and in athymic nude mice. Biomed Pharmacothe. 2018;103:1708–1719.
   PubMed Web of Science ®Google Scholar
• Li X, Xu Z, Jiang Z, et al. Hypoglycemic effect of catalpol on high-fat diet/streptozotocin-induced diabetic mice by increasing skeletal muscle mitochondrial biogenesis. Acta Biochim Biophys Sin (Shanghai). 2014;46:738–748.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Y, Xu M, et al. Catalpol alleviates ovalbumin-induced asthma in mice: reduced eosinophil infiltration in the lung. Int Immunopharmacol. 2017;43:140–146.
   PubMed Web of Science ®Google Scholar
• Bi J, Jiang B, Liu JH, et al. Protective effects of catalpol against H2O2-induced oxidative stress in astrocytes primary cultures. Neurosci Lett. 2008;442:224–227.
   PubMed Web of Science ®Google Scholar
• Cai Q, Ma T, Li C, et al. Catalpol Protects Pre-Myelinating Oligodendrocytes against Ischemia-induced Oxidative Injury through ERK1/2 Signaling Pathway. Int J Biol Sci. 2016;12:1415–1426.
   PubMed Web of Science ®Google Scholar
• Zhang YP, Pan CS, Yan L, et al. Catalpol restores LPS-elicited rat microcirculation disorder by regulation of a network of signaling involving inhibition of TLR-4 and SRC. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1091–G104.
   PubMed Web of Science ®Google Scholar
• Zhou J, Xu G, Ma S, et al. Catalpol ameliorates high-fat diet-induced insulin resistance and adipose tissue inflammation by suppressing the JNK and NF-kappaB pathways. Biochem Biophys Res Commun. 2015;467:853–858.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu ZM, Yang YP, et al. Catalpol ameliorates LPS-induced endometritis by inhibiting inflammation and TLR4/NF-kappaB signaling. J Zhejiang Univ Sci B. 2019;20:816–827.
   PubMed Web of Science ®Google Scholar
• Hu H, Wang C, Jin Y, et al. Catalpol Inhibits Homocysteine-induced Oxidation and Inflammation via Inhibiting Nox4/NF-kappaB and GRP78/PERK Pathways in Human Aorta Endothelial Cells. Inflammation. 2019;42:64–80.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu P, Zhang L, et al. Autophagy inhibition attenuates the induction of anti-inflammatory effect of catalpol in liver fibrosis. Biomed Pharmacother. 2018;103:1262–1271.
   PubMed Web of Science ®Google Scholar
• Fan X, Yan K, Meng Q, et al. Abnormal expression of SIRTs in psoriasis: decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7. Int J Mol Med. 2019;44:157–171.
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Czerwinska J, Placek W. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27:17–23.
   PubMed Web of Science ®Google Scholar
• Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or Immune Cells - Which Is the Trigger? Dermatology. 2019;235:91–100.
   PubMed Web of Science ®Google Scholar
• Xiao S, Li B, Feng S, et al. Acupuncture combined with herbal medicine versus herbal medicine alone for plaque psoriasis: a systematic review protocol. Ann Transl Med. 2019;7:115.
   PubMed Web of Science ®Google Scholar
• Deng J, Yao D, Lu C, et al. Oral Chinese herbal medicine for psoriasis vulgaris: protocol for a randomised, double-blind, double-dummy, multicentre clinical trial. BMJ Open. 2017;7:e014475.
   PubMedGoogle Scholar
• Chuang SY, Lin CH, Sung CT, et al. Murine models of psoriasis and their usefulness for drug discovery. Expert Opin Drug Discov. 2018;13:551–562.
   PubMed Web of Science ®Google Scholar
• Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013;43:3138–3146.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PloS One. 2013;8:e67078.
   PubMed Web of Science ®Google Scholar
• Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, et al. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev. 2002;22:146–167.
   PubMed Web of Science ®Google Scholar
• Mitsui A, Tada Y, Shibata S, et al. Deficiency of both L-selectin and ICAM-1 exacerbates imiquimod-induced psoriasis-like skin inflammation through increased infiltration of antigen presenting cells. Clin Immunol. 2015;157:43–55.
   PubMed Web of Science ®Google Scholar
• Vermi W, Riboldi E, Wittamer V, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med. 2005;201:509–515.
   PubMed Web of Science ®Google Scholar
• Sandgren S, Wittrup A, Cheng F, et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem. 2004;279:17951–17956.
   PubMed Web of Science ®Google Scholar
• An J, Li T, Dong Y, et al. Terminalia Chebulanin Attenuates Psoriatic Skin Lesion via Regulation of Heme Oxygenase-1. Cell Physiol Biochem. 2016;39:531–543.
   PubMedGoogle Scholar
• Ayed Y, Sghaier RM, Laouini D, et al. Evaluation of anti-proliferative and anti-inflammatory activities of Pelagia noctiluca venom in Lipopolysaccharide/Interferon-gamma stimulated RAW264.7 macrophages. Bio pharmacoth. 2016;84:1986–1991.
   Google Scholar
• Yan L, Hu X, Wu Q, et al. CQMUH-011, a novel adamantane sulfonamide compound, inhibits lipopolysaccharide- and D-galactosamine-induced fulminant hepatic failure in mice. Int Immunopharmacol. 2017;47:231–243.
   PubMed Web of Science ®Google Scholar
• Irrera N, Vaccaro M, Bitto A, et al. BAY 11-7082 inhibits the NF-kappaB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci (Lond). 2017;131:487–498.
   PubMed Web of Science ®Google Scholar
• Yang BY, Cheng YG, Liu Y, et al. Datura Metel L. Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis and Inhibits Inflammatory Cytokines Production through TLR7/8-MyD88-NF-kappaB-NLRP3 Inflammasome Pathway. Molecules. 2019;24.
   PubMed Web of Science ®Google Scholar
• Chamcheu JC, Esnault S, Adhami VM, et al. Fisetin, a 3,7,3ʹ,4ʹ-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. Cells. 2019;8.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Au SC, Kim N, et al. NF-kappaB: an essential transcription factor in psoriasis. J Dermatol Sci. 2013;69:89–94.
   PubMed Web of Science ®Google Scholar
• Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124:1275–1283.
   PubMed Web of Science ®Google Scholar
• Chen H, Lu C, Liu H, et al. Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-kappaB pathway. Int Immunopharmacol. 2017;48:110–117.
   PubMed Web of Science ®Google Scholar
• Wang A, Wei J, Lu C, et al. Genistein suppresses psoriasis-related inflammation through a STAT3-NF-kappaB-dependent mechanism in keratinocytes. Int Immunopharmacol. 2019;69:270–278.
   PubMed Web of Science ®Google Scholar
• Wang H, Syrovets T, Kess D, et al. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol. 2009;183:4755–4763.
   PubMed Web of Science ®Google Scholar
• Bahar-Shany K, Ravid A, Koren R. Upregulation of MMP-9 production by TNFalpha in keratinocytes and its attenuation by vitamin D. J Cell Physiol. 2010;222:729–737.
   PubMed Web of Science ®Google Scholar
• Kwon DJ, Bae YS, Ju SM, et al. Casuarinin suppresses TNF-alpha-induced ICAM-1 expression via blockade of NF-kappaB activation in HaCaT cells. Biochem Biophys Res Commun. 2011;409:780–785.
   PubMed Web of Science ®Google Scholar
• Xiong H, Xu Y, Tan G, et al. Glycyrrhizin ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice and inhibits TNF-alpha-induced ICAM-1 expression via NF-kappaB/MAPK in HaCaT cells. Cell Physiol Biochem. 2015;35:1335–1346.
   PubMed Web of Science ®Google Scholar
• Yu J, Xiao Z, Zhao R, et al. Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts anti-psoriatic effect. Life Sci. 2017;180:17–22.
   PubMed Web of Science ®Google Scholar
• Yu J, Xiao Z, Zhao R, et al. Astilbin emulsion improves guinea pig lesions in a psoriasis-like model by suppressing IL-6 and IL-22 via p38 MAPK. Mol Med Rep. 2018;17:3789–3796.
   PubMed Web of Science ®Google Scholar
• Mo C, Shetti D, Wei K. Erianin Inhibits Proliferation and Induces Apoptosis of HaCaT Cells via ROS-Mediated JNK/c-Jun and AKT/mTOR Signaling Pathways. Molecules. 2019;24.
   PubMedGoogle Scholar
• Chen L, Wu J, Ren W, et al. c-Jun N-terminal kinase (JNK)-phospho-c-JUN (ser63/73) pathway is essential for FOXP3 nuclear translocation in psoriasis. J Dermatol Sci. 2013;69:114–121.
   PubMed Web of Science ®Google Scholar
• Huang X, Yu P, Liu M, et al. ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway. Int Immunopharmacol. 2019;66:236–241.
   PubMed Web of Science ®Google Scholar
• Gao M, Si X. Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo. Exp Dermatol. 2018;27:1112–1119.
   PubMed Web of Science ®Google Scholar
• Qiang L, Sample A, Liu H, et al. Epidermal SIRT1 regulates inflammation, cell migration, and wound healing. Sci Rep. 2017;7:14110.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Yao H, Caito S, et al. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med. 2013;61:95–110.
   PubMed Web of Science ®Google Scholar
• Xu F, Xu J, Xiong X, et al. Salidroside inhibits MAPK, NF-kappaB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox rep commun free rad res. 2019;24:70–74.
   Google Scholar
• Lai T, Wen X, Wu D, et al. SIRT1 protects against urban particulate matter-induced airway inflammation. Int J Chron Obstruct Pulmon Dis. 2019;14:1741–1752.
   PubMed Web of Science ®Google Scholar
• Rada P, Pardo V, Mobasher MA, et al. SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress. Antioxid Redox Signal. 2018;28:1187–1208.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huo J, Zhang D, et al. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-kappaB signaling. J Cell Biochem. 2019;120:6459–6470.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Suarez-Farinas M, Cueto I, et al. A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. PloS One. 2015;10:e0142081.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Shi L, Wang L, et al. Activation of sirtuin 1 by catalpol-induced down-regulation of microRNA-132 attenuates endoplasmic reticulum stress in colitis. Pharmacol Res. 2017;123:73–82.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bi R, Meng Q, et al. Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro. Br J Pharmacol. 2019;176:4558–4573.
   PubMed Web of Science ®Google Scholar